Eliminating the Need for Fasting with Oral Administration of Bisphosphonates

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2013 Nov 9

PMID 24204155

Citations 20

Authors

Michael Pazianas

Bo Abrahamsen

Serge Ferrari

R Graham G Russell

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates are the major treatment of choice for osteoporosis, given that they are attached preferentially by bone and significantly reduce the risk of fractures. Oral bisphosphonates are poorly absorbed (usually less than 1% for nitrogen-containing bisphosphonates) and when taken with food or beverages create complexes that cannot be absorbed. For this reason, they must be taken on an empty stomach, and a period of up to 2 hours must elapse before the consumption of any food or drink other than plain water. This routine is not only inconvenient but can lead to discontinuation of treatment, and when mistakenly taken with food, may result in misdiagnosis of resistance to or failure of treatment. The development of an enteric-coated delayed-release formulation of risedronate with the addition of the calcium chelator, ethylenediaminetetraacetic acid (EDTA), a widely used food stabilizer, eliminates the need for fasting without affecting the bioavailability of risedronate or its efficacy.

Citing Articles

Piperazine-Derived Bisphosphonate-Based Ionizable Lipid Nanoparticles Enhance mRNA Delivery to the Bone Microenvironment.

Yoon I, Xue L, Chen Q, Liu J, Xu J, Siddiqui Z Angew Chem Int Ed Engl. 2024; 64(3):e202415389.

PMID: 39379320 PMC: 11735871. DOI: 10.1002/anie.202415389.

Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.

Casado E, Rosas J, Rubio-Terres C, Rubio-Rodriguez D, Boolell M, Aristegui I J Comp Eff Res. 2023; 12(11):e230115.

PMID: 37712635 PMC: 10690429. DOI: 10.57264/cer-2023-0115.

Surface-Modified Silica Hydrogels for the Programmable Release of Bisphosphonate Anti-Osteoporosis Drugs: The Case of Etidronate.

Alatzoglou F, Vassaki M, Nirgianaki K, Tripodianos E, Turhanen P, Demadis K Materials (Basel). 2023; 16(9).

PMID: 37176259 PMC: 10180253. DOI: 10.3390/ma16093379.

Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.

Eisman J, Cortet B, Boolell M, Ionescu-Ittu R, Vekeman F, Heroux J Osteoporos Int. 2023; 34(5):977-991.

PMID: 36872338 PMC: 10104910. DOI: 10.1007/s00198-022-06627-0.

Hyaluronic acid-alendronate conjugate: A macromolecular drug delivery system for intra-articular treatment of osteoarthritis.

Pluda S, Beninatto R, Soato M, Barbera C, Di Lucia A, Fassina L Osteoarthr Cartil Open. 2022; 3(2):100159.

PMID: 36474988 PMC: 9718194. DOI: 10.1016/j.ocarto.2021.100159.

References

Boulenc X, Marti E, Joyeux H, Roques C, Berger Y, Fabre G . Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Biochem Pharmacol. 1993; 46(9):1591-600. DOI: 10.1016/0006-2952(93)90328-t. View

Kothawala P, Badamgarav E, Ryu S, Miller R, Halbert R . Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007; 82(12):1493-501. DOI: 10.1016/S0025-6196(11)61093-8. View

Reid I, Miller P, Brown J, Kendler D, Fahrleitner-Pammer A, Valter I . Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010; 25(10):2256-65. DOI: 10.1002/jbmr.149. View

Dunn C, Goa K . Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. 2001; 61(5):685-712. DOI: 10.2165/00003495-200161050-00013. View

Janner M, Muhlbauer R, Fleisch H . Sodium EDTA enhances intestinal absorption of two bisphosphonates. Calcif Tissue Int. 1991; 49(4):280-3. DOI: 10.1007/BF02556218. View

Ruifrok P, Mol W . Paracellular transport of inorganic and organic ions across the rat ileum. Biochem Pharmacol. 1983; 32(4):637-40. DOI: 10.1016/0006-2952(83)90487-2. View

Stephenson J . Noncompliance may cause half of antihypertensive drug "failures". JAMA. 1999; 282(4):313-4. DOI: 10.1001/jama.282.4.313. View

Khalil I, Kogure K, Akita H, Harashima H . Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev. 2006; 58(1):32-45. DOI: 10.1124/pr.58.1.8. View

Hansen C, Pedersen B, Konradsen H, Abrahamsen B . Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int. 2012; 24(7):2079-97. DOI: 10.1007/s00198-012-2221-5. View

10.

Pazianas M, Compston J, Huang C . Atrial fibrillation and bisphosphonate therapy. J Bone Miner Res. 2010; 25(1):2-10. DOI: 10.1359/jbmr.091201. View

11.

Mitchell D, Barr W, Eusebio R, STEVENS K, Duke F, Russell D . Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res. 2001; 18(2):166-70. DOI: 10.1023/a:1011024200280. View

12.

McClung M, Miller P, Brown J, Zanchetta J, Bolognese M, Benhamou C . Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int. 2011; 23(1):267-76. PMC: 3249191. DOI: 10.1007/s00198-011-1791-y. View

13.

FOREMAN H, TRUJILLO T . The metabolism of C14 labeled ethylenediaminetetraacetic acid in human beings. J Lab Clin Med. 1954; 43(4):566-71. View

14.

Porras A, Holland S, Gertz B . Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999; 36(5):315-28. DOI: 10.2165/00003088-199936050-00002. View

15.

McClung M, Balske A, Burgio D, Wenderoth D, Recker R . Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos Int. 2012; 24(1):301-10. PMC: 3536960. DOI: 10.1007/s00198-012-2175-7. View

16.

Blanusa M, Varnai V, Piasek M, Kostial K . Chelators as antidotes of metal toxicity: therapeutic and experimental aspects. Curr Med Chem. 2005; 12(23):2771-94. DOI: 10.2174/092986705774462987. View

17.

Pazianas M, Cooper C, Ebetino F, Russell R . Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010; 6:325-43. PMC: 2909499. DOI: 10.2147/tcrm.s8054. View

18.

Viswanathan M, Golin C, Jones C, Ashok M, Blalock S, Wines R . Closing the quality gap: revisiting the state of the science (vol. 4: medication adherence interventions: comparative effectiveness). Evid Rep Technol Assess (Full Rep). 2014; (208.4):1-685. PMC: 4780896. View

19.

Pazianas M, Epstein S, Zaidi M . Evaluating the antifracture efficacy of bisphosphonates. Rev Recent Clin Trials. 2009; 4(2):122-30. DOI: 10.2174/157488709788186030. View

20.

Chavassieux P, Arlot M, Reda C, Wei L, Yates A, Meunier P . Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100(6):1475-80. PMC: 508326. DOI: 10.1172/JCI119668. View